Intravitreal ranibizumab and bevacizumab: a review of risk (Q36925652)

17 August 2017

1 reference

title

Intravitreal ranibizumab and bevacizumab: a review of risk (English)

1 reference

17 August 2017

1 reference

Rima M Dafer

1

1 reference

17 August 2017

Michael Schneck

series ordinal

2

1 reference

17 August 2017

Thomas R Friberg

series ordinal

3

1 reference

17 August 2017

Walter M Jay

series ordinal

4

1 reference

17 August 2017

language of work or name

English

0 references

publication date

1 July 2007

1 reference

Seminars in Ophthalmology

17 August 2017

1 reference

17 August 2017

22

1 reference

17 August 2017

3

1 reference

17 August 2017

201-204

1 reference

Vascular endothelial growth factor: basic science and clinical progress

17 August 2017

1 reference

https://api.crossref.org/works/10.1080%2F08820530701543024

Cardiovascular risk factors and the long-term incidence of age-related macular degeneration: the Blue Mountains Eye Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08820530701543024

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08820530701543024

Risk factors associated with age-related macular degeneration. A case-control study in the age-related eye disease study: Age-Related Eye Disease Study Report Number 3

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08820530701543024

Risk factors for the incidence of Advanced Age-Related Macular Degeneration in the Age-Related Eye Disease Study (AREDS) AREDS report no. 19

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08820530701543024

Cardiovascular disease, its risk factors and treatment, and age-related macular degeneration: Women's Health Initiative Sight Exam ancillary study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08820530701543024

21 January 2018

The eye in hypertension

1 reference

https://api.crossref.org/works/10.1080%2F08820530701543024

Blood pressure, atherosclerosis, and the incidence of age-related maculopathy: the Rotterdam Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08820530701543024

Complement factor H polymorphism, complement activators, and risk of age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08820530701543024

Progression of age-related macular degeneration: prospective assessment of C-reactive protein, interleukin 6, and other cardiovascular biomarkers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08820530701543024

Apolipoprotein E gene and early age-related maculopathy: the Atherosclerosis Risk in Communities Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08820530701543024

Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08820530701543024

Ranibizumab for neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08820530701543024

Ranibizumab versus verteporfin for neovascular age-related macular degeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08820530701543024

Some ethical considerations for the "off-label" use of drugs such as Avastin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08820530701543024

Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08820530701543024

The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08820530701543024

The international intravitreal bevacizumab safety survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08820530701543024

Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08820530701543024

Vascular Endothelial Growth Factor Expression and Angiogenesis Induced by Chronic Cerebral Hypoperfusion in Rat Brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08820530701543024

VEGF-induced neuroprotection, neurogenesis, and angiogenesis after focal cerebral ischemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08820530701543024

VEGF-overexpressing transgenic mice show enhanced post-ischemic neurogenesis and neuromigration

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08820530701543024

VEGF overexpression enhances striatal neurogenesis in brain of adult rat after a transient middle cerebral artery occlusion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08820530701543024

Vascular endothelial growth factor and angiopoietins in focal cerebral ischemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08820530701543024

Vascular endothelial growth factor antagonist reduces brain edema formation and venous infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08820530701543024

Effects of anti-VEGF antibody on blood-brain barrier disruption in focal cerebral ischemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08820530701543024

10.1080/08820530701543024

21 January 2018

Identifiers

DOI

1 reference

17 August 2017

1 reference